Sirtris Pharmaceuticals to Present at the FASEB Summer Research Conferences

  
    
  
  
    
      Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical 
      company focused on discovering and developing small molecule drugs to 
      treat diseases of aging such as Type 2 Diabetes, announced today that it 
      will present two posters at the Federation of American Societies for 
      Experimental Biology (FASEB) Summer Research Conferences from August 4 
      to August 9, 2007.
    
    
      The "Glucose Transporter Biology" poster will be presented in Snowmass 
      Village, Colorado; and the "Obesity, Energy Balance & Disease" poster 
      will be presented in Indian Wells, California. The data presented offer 
      mechanistic insight on SIRT1 activation via resveratrol and via new 
      chemical entities (NCEs), which are structurally unrelated to and 
      significantly more potent than resveratrol, as demonstrated in 
      pre-clinical studies. Data showing glucose lowering and improved insulin 
      sensitivity with NCEs in multiple pre-clinical models of Type 2 Diabetes 
      such as diet induced obesity model, ob/ob, and Zucker fa/fa, also will 
      be presented.
    
    
      About Sirtris Pharmaceuticals
    
    
      Sirtris Pharmaceuticals is a biopharmaceutical company focused on 
      discovering and developing proprietary, orally available, small molecule 
      drugs with the potential to treat diseases associated with aging, 
      including metabolic diseases such as Type 2 Diabetes. Our drug 
      candidates are designed to mimic certain beneficial health effects of 
      calorie restriction, without requiring a change in eating habits, by 
      activation of sirtuins, a recently discovered class of enzymes that 
      control the aging process. The company's headquarters are in Cambridge, 
      Massachusetts.
    
    
      This press release contains forward-looking statements within the 
      meaning of the Private Securities Litigation Reform Act of 1995. Such 
      statements include, but are not limited to, Sirtris Pharmaceuticals, its 
      product candidates and those candidates’ 
      clinical potential. These forward-looking statements about future 
      expectations, plans and prospects of Sirtris Pharmaceuticals involve 
      significant risks, uncertainties and assumptions, including risks 
      related to the lack of results that would provide a basis for predicting 
      whether any of the Company’s product 
      candidates will be safe or effective, or receive regulatory approval, 
      the possibility that results of pre-clinical studies are not necessarily 
      predictive of clinical trial results, the Company's potential inability 
      to initiate and complete pre-clinical studies and clinical trials for 
      its product candidates, the fact that none of the Company's product 
      candidates has received regulatory approvals, the fact that none of the 
      results from pre-clinical studies may be achieved in clinical studies, 
      the potential inability of the Company to gain market acceptance of the 
      Company's product candidates, and those other risks factors that can be 
      found in the Company's filings with the Securities and Exchange 
      Commission. Actual results may differ materially from those Sirtris 
      Pharmaceuticals contemplated by these forward-looking statements. 
      Sirtris Pharmaceuticals does not undertake to update any of these 
      forward-looking statements to reflect a change in its views or events or 
      circumstances that occur after the date of this release.